except
clean
water
vaccin
effect
modal
reduc
human
mortal
infecti
diseas
effect
vaccin
world
health
organ
abl
declar
complet
erad
smallpox
around
world
similarli
world
almost
free
polio
except
six
countri
cdc
effect
vaccin
success
develop
pathogen
howev
lack
effect
vaccin
other
eg
bacillicaletteguerin
bcg
base
vaccin
tuberculosi
emerg
new
pathogen
eg
sever
acut
respiratori
syndrom
sar
viru
warrant
continu
effort
vaccin
develop
addit
recent
bioterror
threat
make
urgent
develop
new
altern
vaccin
pathogen
potenti
use
bioterror
purpos
vaccin
tradit
prepar
either
live
attenu
kill
bacteria
virus
mani
case
approach
proven
success
vaccin
base
live
attenu
kill
pathogen
usual
potent
induc
aspect
immun
respons
howev
seriou
safeti
concern
may
preclud
use
approach
develop
vaccin
pathogen
hiv
baba
et
al
new
gener
vaccin
recombin
proteinbas
vaccin
synthet
peptidebas
vaccin
lipidbas
vaccinesantigen
vaccin
base
polysaccharid
thought
potenti
safer
tradit
vaccin
unfortun
new
gener
vaccin
often
poorli
immunogen
partial
compon
adjuv
activ
discard
purif
synthesi
process
less
well
defin
structur
pathogen
bacteri
cell
wall
compon
unmethyl
dna
doublestrand
ds
rna
may
activ
host
defens
system
act
potent
danger
signal
elimin
compon
lead
poor
immunogen
reduc
lack
abil
new
gener
vaccin
induc
cellmedi
immun
cmi
respons
especi
cytotox
lymphocyt
respons
ctl
anoth
limit
exampl
recombin
proteinbas
vaccin
elicit
mainli
humor
immun
respons
ie
igg
ige
product
administ
without
proper
adjuv
polysaccharid
vaccin
without
conjug
appropri
carrier
protein
gener
cell
independ
ti
respons
product
igm
lesinski
westerink
importantli
current
believ
cmi
especi
ctl
respons
critic
neutral
antibodi
effect
control
intracellular
pathogen
hiv
hepat
tuberculosi
malaria
case
tumor
vaccin
abil
induc
tumorspecif
ctl
respons
thought
indispens
effect
therefor
discoveri
earli
vaccin
base
plasmid
dna
induc
humor
cellular
immun
respons
produc
great
excit
vaccin
immunolog
commun
mani
differ
term
genet
vaccin
polynucleotid
vaccin
nucleic
acid
vaccin
use
name
dna
vaccin
chose
term
nucleic
acid
vaccin
subterm
dna
vaccin
rna
vaccin
dna
vaccin
base
find
administr
recombin
plasmid
dna
anim
result
express
foreign
protein
encod
plasmid
wolff
et
al
soon
initi
find
tang
et
al
first
time
demonstr
elicit
immun
respons
foreign
protein
introduc
plasmid
encod
interest
antigen
protein
directli
mous
skin
gene
gun
almost
simultan
ulmer
et
al
fynan
et
al
show
immun
plasmid
dna
could
protect
mice
lethal
influenza
challeng
subsequ
thousand
paper
publish
demonstr
dna
vaccin
potenti
effect
wide
varieti
diseas
includ
infecti
diseas
cancer
autoimmun
diseas
allerg
diseas
gener
dna
vaccin
interest
antigenencod
gene
insert
bacteri
plasmid
control
appropri
eukaryot
promot
eg
cmv
promot
cytomegaloviru
case
due
differ
codon
usag
prefer
bacteria
eukaryot
cell
antigen
gene
often
modifi
point
mutat
improv
effici
dna
vaccin
gene
express
purifi
detoxifi
plasmid
dna
bacteria
administ
host
anim
plasmid
pick
appropri
cell
made
way
nuclei
host
cell
use
gene
transcript
protein
express
machin
produc
interest
antigen
host
regard
express
antigen
foreign
mount
immun
respons
addit
appropri
number
unmethyl
cpg
motif
right
flank
sequenc
usual
engin
backbon
plasmid
explain
later
cpg
motif
immunostimulatori
induc
product
type
cytokin
etc
upregul
costimulatori
molecul
antigenpres
cell
apc
shimada
et
al
tokunaga
et
al
yamamoto
et
al
addit
abil
elicit
humor
cellular
immun
respons
dna
vaccin
thought
potenti
safer
tradit
vaccin
rel
stabl
potenti
costeffect
manufactur
storag
also
multipl
antigen
may
combin
one
plasmid
target
multipl
pathogen
multipl
compon
singl
pathogen
addit
unmethyl
cpg
motif
bacteri
plasmid
dna
context
flank
sequenc
proven
immunostimulatori
act
pathogen
associ
molecular
pattern
pamp
molecul
interact
tolllik
receptor
howev
dna
vaccin
limit
specif
dna
vaccin
tend
rel
poorli
immunogen
often
requir
larg
dose
effect
sinc
discoveri
earli
dna
vaccin
mainli
administ
either
intramuscular
im
inject
nake
plasmid
dna
gene
gunmedi
administr
ie
ballist
penetr
pdna
adsorb
gold
bead
skin
intramuscular
inject
proven
effect
small
anim
model
howev
effect
dna
vaccin
nonhuman
primat
human
recent
studi
encourag
especi
elicit
antibodi
respons
calarota
et
al
conri
et
al
klenck
et
al
le
et
al
mincheff
et
al
rosenberg
et
al
tacket
et
al
tagawa
et
al
timmerman
et
al
wang
et
al
weber
et
al
gene
gunmedi
administr
result
better
immun
respons
intramuscular
inject
clinic
trial
roy
et
al
howev
administr
gold
bead
human
might
problemat
long
term
state
hilleman
vaccinologist
knowledg
immunolog
essenti
simpl
gener
immun
respons
includ
antibodi
product
humor
immun
respons
ctl
respons
cytokinemedi
type
type
helper
respons
addit
apc
b
lymphocyt
known
detector
cell
toxic
cell
b
lymphocyt
known
effector
cell
known
facilit
determin
type
immun
respons
known
order
success
induc
primari
immun
respons
profession
apc
requir
profession
apc
provid
first
signal
secondari
signal
requir
success
antigen
present
almost
cell
express
mhc
class
molecul
profession
apc
express
induc
express
secondari
signal
molecul
interact
peptid
epitopeload
mhc
molecul
cell
receptor
tcr
without
appropri
secondari
signal
lead
anergi
dendrit
cell
dc
potent
antigenpres
cell
banchereau
steinman
immatur
dc
langerhan
cell
lc
extrem
well
equip
antigen
captur
captur
antigen
induc
matur
mobil
dc
banchereau
steinman
light
find
success
antigen
must
make
way
apc
especi
dc
initi
primari
immun
respons
outcom
immun
respons
determin
partial
antigen
present
apc
b
cell
exogen
endogen
live
vaccin
live
viral
vaccin
viru
still
infecti
host
cell
includ
apc
relev
antigen
produc
host
cell
therefor
antigen
gener
insid
cell
endogen
process
proteosom
apparatu
small
peptid
transfer
endoplasm
reticulum
bind
newli
synthes
mhc
class
molecul
hard
song
mhc
class
molecul
peptid
epitop
groov
mobil
onto
cell
surfac
may
recogn
antigenspecif
cell
appropri
tcr
endogen
present
result
ctl
immun
respons
fact
dna
vaccin
may
elicit
ctl
immun
respons
also
due
endogen
present
encod
antigen
howev
nonliv
vaccin
protein
subunit
base
vaccin
antigen
taken
apc
intercellular
space
endocytosi
pathway
antigen
process
insid
endosom
lysosom
endosom
proteolyt
degrad
product
occupi
epitop
groov
class
ii
mhc
molecul
transport
extracellular
surfac
apc
class
ii
mhc
molecul
togeth
epitop
avail
recognit
cell
cell
may
develop
either
type
type
cell
cell
relat
cytokin
interferon
ifn
etc
help
initi
cmi
wherea
helper
relat
cytokin
etc
direct
humor
immun
respons
castellino
et
al
mention
earlier
dna
vaccin
plasmid
dna
primarili
administ
either
im
inject
via
gene
gun
skin
found
gene
express
administ
plasmid
predominantli
myoblast
im
inject
keratinocyt
fibroblast
gene
gunmedi
administr
pattern
express
rais
question
express
antigen
present
cell
although
myoblast
keratinocyt
express
mhc
class
molecul
express
secondari
signal
molecul
eg
cd
cd
therefor
theoret
present
express
antigen
nonprofession
cell
like
toler
stimul
cell
addit
experi
carri
iwasaki
et
al
corr
et
al
clearli
rule
possibl
somat
cell
transfect
plasmid
express
antigen
directli
present
antigen
cell
studi
corr
et
al
parent
bone
marrow
chimera
bxd
recipi
mice
receiv
bone
marrow
express
b
mhc
molecul
inject
im
nake
plasmid
dna
encod
nucleoprotein
influenza
strain
epitop
b
singl
antigen
result
ctl
respons
restrict
mhc
haplotyp
bone
marrow
alon
haplotyp
express
myocyt
recipi
corr
et
al
result
show
dendrit
cell
apc
differenti
bone
marrow
cell
instead
somat
cell
respons
antigen
present
may
explain
intraderm
gene
gun
inject
often
induc
better
immun
respons
im
inject
gene
gun
may
target
dc
viabl
skin
epidermi
effect
directli
result
potent
immun
respons
moreov
significantli
less
dna
requir
elicit
immun
respons
gene
gun
compar
im
needl
inject
within
skin
high
popul
immatur
dc
lc
contrast
much
fewer
dc
exist
muscl
current
three
propos
mechan
antigen
present
dna
vaccin
direct
transfect
profession
apc
ie
dc
present
express
antigen
profession
apc
direct
prime
modifi
somat
cell
myocyt
keratinocyt
crossprim
plasmid
dna
transfect
somat
cell
andor
profession
apc
protein
secret
transfect
cell
taken
profession
apc
present
cell
gurunathan
et
al
liu
takashima
morita
first
mechan
direct
transfect
profession
apc
present
selfexpress
antigen
apc
easili
understand
well
document
report
transfect
mous
dc
suffici
success
elicit
immun
respons
takashima
morita
mani
experi
also
demonstr
exist
crossprim
crossprim
antigen
may
express
somat
cell
transfect
plasmid
dna
antigen
protein
peptid
pick
profession
apc
present
cell
aforement
secret
exogen
protein
undergo
endocytosi
phagocytosi
enter
mhc
class
ii
antigen
process
pathway
stimul
cell
endogen
produc
protein
process
proteosom
apparatu
present
mhc
class
pathway
stimul
naiv
cell
although
peptid
deriv
exogen
sourc
gener
present
mhc
class
molecul
mani
exampl
show
occur
proper
adjuv
deliveri
system
use
falo
et
al
raychaudhuri
rock
crossprim
antigen
peptid
mhc
class
ii
gener
somat
cell
myocyt
keratinocyt
taken
profession
apc
prime
tcell
respons
studi
carri
ulmer
et
al
clearli
demonstr
crossprim
myocyt
apc
happen
studi
influenza
npexpress
myoblast
k
inject
intraperiton
hybrid
mice
dxk
ulmer
et
al
found
np
ctl
restrict
mhc
haplotyp
parent
strain
induc
restrict
epitop
must
somehow
found
way
move
myoblast
express
apc
cours
assum
unlik
case
direct
transfer
np
express
plasmid
myoblast
apc
happen
direct
prime
transfect
somat
cell
mechan
theoret
unlik
howev
agadjanyan
et
al
point
mice
vaccin
dna
encod
antigen
transfect
muscl
cell
prime
antigenspecif
ctl
respons
agadjanyan
et
al
case
myoblast
express
envelop
protein
interest
find
alon
provid
necessari
secondari
signal
anoth
studi
show
transfect
fibroblast
abl
induc
antigenspecif
mhc
class
irestrict
respons
physic
reloc
secondari
lymphoid
tissu
kundig
et
al
lymphoid
tissu
secondari
signal
may
provid
cell
fibroblast
thu
nonprofession
cell
may
abl
prime
immun
respons
appropri
secondari
signal
provid
mention
earlier
one
advantag
bacteri
plasmid
dna
vaccin
builtin
power
adjuv
unmethyl
cpg
motif
bacteri
dna
unknowingli
use
experiment
compon
adjuv
year
freund
use
whole
mycobacteri
extract
major
constitu
adjuv
formula
base
empir
result
freund
shown
mycobacteri
dna
freund
adjuv
contribut
adjuv
effect
shimada
et
al
tokunaga
et
al
yamamoto
et
al
yamamoto
et
al
found
purifi
nucleic
acid
fraction
bcg
vaccin
limit
antitumor
activ
appear
mediat
abil
activ
nk
cell
induc
product
interferon
treatment
fraction
dnase
substanti
reduc
activ
tokunaga
et
al
confirm
immunostimulatori
properti
mycobacteri
dna
known
unmethyl
cpg
motif
flank
sequenc
even
form
oligonucleotid
strongli
immunostimulatori
krieg
et
al
unmethyl
cpg
motif
found
ligand
hemmi
et
al
belong
group
tlr
tlr
identifi
major
recognit
receptor
pathogenassoci
molecular
pattern
pamp
lipopolysaccharid
lp
peptidoglycan
lipoteicho
acid
cpgcontain
oligonucleotid
cpg
odn
hemmi
et
al
poltorak
et
al
term
toll
origin
refer
cell
surfac
receptor
govern
dorsalventr
orient
earli
drosophila
larva
stein
et
al
later
found
also
play
crucial
role
antifung
defens
togeth
antimicrobi
peptid
lemaitr
et
al
first
mammalian
protein
structur
relat
drosophila
toll
identifi
call
human
tolllik
receptor
medzhitov
et
al
date
human
murin
transmembran
protein
shown
belong
mammalian
tlr
famili
zaremb
godowski
recent
respond
specif
uropathogen
bacteria
discov
mice
zhang
et
al
toll
tlr
famili
protein
character
presenc
extracellular
domain
leucinerich
repeat
intracytoplasm
region
contain
receptor
homolog
tir
domain
individu
mammalian
tlr
appear
recogn
distinct
microbi
compon
exampl
lp
poltorak
et
al
bacteri
lipoprotein
sblp
alipranti
et
al
yeast
underhil
et
al
flagellin
hayashi
et
al
dsrna
alexopoul
et
al
small
antivir
compound
hemmi
et
al
bacteri
dna
cpgdna
hemmi
et
al
engag
respect
differ
tlr
exert
distinct
overlap
set
biolog
effect
increas
evid
indic
attribut
common
uniqu
aspect
signal
mechan
function
studi
character
tlr
signal
via
receptor
pathway
presenc
tir
domain
interact
adaptor
protein
adaptor
molecul
recruit
receptor
complex
follow
engag
kinas
irak
serinethreonin
kinas
involv
phosphoryl
activ
tumor
necrosi
factor
tnf
receptorassoci
factor
medzhitov
et
al
muzio
et
al
wesch
et
al
contrast
irakm
lack
kinas
activ
regul
tlr
signal
neg
prevent
dissoci
phosphoryl
phosphoryl
lead
activ
downstream
kinas
stress
kinas
ib
kinas
ikk
complex
baud
et
al
event
free
nuclear
factorb
nfb
ib
allow
nuclear
transloc
subsequ
transcript
activ
mani
proinflammatori
gene
encod
cytokin
chemokin
adhes
molecul
immun
receptor
molecul
involv
engag
control
innat
immun
respons
orchestr
transit
adapt
immun
respons
medzhitov
tlr
signal
stimul
matur
dc
migrat
lymph
node
stimul
cell
present
mhc
complex
antigen
present
alon
stimul
pathogenspecif
tcell
clone
suffici
trigger
effici
tcell
expans
clonal
tcell
expans
requir
addit
signal
deliv
costimulatori
molecul
tlr
signal
function
trigger
adapt
immun
enhanc
express
mhc
molecul
also
costimulatori
molecul
dc
stimul
bacteri
cpg
motif
gener
lead
product
cytokin
upregul
costimulatori
molecul
lymphocyt
apc
interact
cpg
motif
confirm
fact
knockout
mice
cpg
dnainduc
effect
includ
cytokin
product
bcell
prolifer
dc
matur
complet
abolish
hemmi
et
al
fact
immunostimulatori
effect
cpg
motif
strong
cpg
motif
contain
oligonucleotid
use
vaccin
adjuv
tumor
vaccin
develop
cpg
motif
adjuv
special
interest
gener
cpg
motif
skew
immun
respons
bias
favor
induct
ctl
tumor
kill
howev
caution
need
appli
repeat
administr
cpg
motif
heikenwald
et
al
report
repeat
cpg
oligodeoxynucleotid
administr
led
lymphoid
follicl
destruct
immunosuppress
heikenwald
et
al
report
daili
intraperiton
inject
g
cpgodn
dramat
alter
morpholog
function
mous
lymphoid
organ
day
lymphoid
follicl
poorli
defin
follicular
dendrit
cell
germin
center
b
lymphocyt
suppress
accordingli
cpgodn
treatment
day
strongli
reduc
primari
humor
immun
respons
immunoglobulin
class
switch
day
mice
develop
multifoc
liver
necrosi
hemorrhag
ascit
cours
unlik
anybodi
develop
vaccin
contain
mani
cpg
motif
administ
daili
day
intraperiton
find
mention
simpli
point
high
dose
cpg
motif
could
potenti
toxic
dna
vaccin
origin
administ
intramuscular
inject
via
gene
gun
skin
two
continu
main
mean
rout
administr
meanwhil
mani
rout
tri
includ
subcutan
inject
intraderm
inject
noninvas
topic
applic
onto
skin
tang
et
al
intranas
intravagin
applic
livingston
et
al
park
et
al
vaccin
via
oral
mucosa
gastrointestin
gi
mucosa
oral
depend
rout
differ
immun
respons
elicit
exampl
due
fact
pathogen
enter
host
either
mucos
surfac
skin
immun
respons
neutral
kill
pathogen
mucos
surfac
prior
entranc
therefor
desir
also
due
common
mucos
system
dose
vaccin
one
mucos
site
eg
nasal
may
lead
mucos
respons
anoth
mucos
site
eg
vagin
mcghee
et
al
achiev
mucos
immun
respons
dna
vaccin
appli
nasal
oral
gi
vagin
mucos
surfac
special
design
devic
deliveri
system
follow
paragraph
provid
exampl
administr
dna
vaccin
mucos
rout
oral
buccal
mucosa
cover
network
dc
analog
lc
skin
lc
repres
major
apc
human
buccal
mucosa
epithelium
addit
high
densiti
cell
mucosalassoci
lymphoid
tissu
malt
present
buccal
mucosa
therefor
immun
via
buccal
mucosa
may
repres
attract
mucos
immun
approach
fact
efficaci
oral
buccal
mucos
dna
immun
confirm
mani
use
transepitheli
needl
inject
jet
inject
gene
gun
exampl
lundholm
et
al
found
jet
inject
plasmid
dna
oral
cheek
mice
induc
strong
iga
mucos
respons
specif
encod
protein
tat
lundholm
et
al
avoid
inconveni
pose
mean
dna
administr
cui
mumper
develop
buccal
mucoadhes
film
base
polym
noveon
eudragit
plasmid
dna
encod
galactosidas
protein
model
antigen
load
film
appli
rabbit
buccal
mucosa
serumspecif
igg
level
compar
induc
subcutan
inject
aluminum
hydroxid
alum
adjuvantedgalactosidas
protein
induc
cui
mumper
addit
strong
serum
iga
splenocyt
prolif
respons
induc
although
data
promis
applic
vaccin
oral
buccal
mucosa
limit
toler
instead
immun
might
often
induc
buccal
mucosa
contact
mani
foreign
antigen
daili
howev
rare
immun
respons
induc
oral
administr
vaccin
desir
immunolog
aspect
patient
complianc
point
view
oral
administr
vaccin
conveni
patient
may
make
larg
popul
immun
feasibl
moreov
oral
administr
vaccin
shown
induc
system
mucos
immun
respons
russelljon
intestin
mucosa
rich
dc
malt
howev
polio
vaccin
still
market
vaccin
administ
oral
perhap
illustr
difficulti
develop
effect
oral
vaccin
extens
enzymat
system
harsh
physic
chemic
environ
gi
tract
make
difficult
develop
activ
oral
vaccin
therefor
dna
vaccin
oral
administr
experiment
level
often
encapsul
particl
encapsul
dna
insid
microparticl
may
provid
protect
dna
jone
et
al
report
first
oral
dna
vaccin
encapsul
plasmidexpress
insect
luciferas
protein
plga
microparticl
administ
mice
oral
gavag
jone
et
al
author
observ
good
serum
igg
iga
igm
antibodi
respons
importantli
signific
level
mucos
iga
saliva
stool
sampl
contrast
unencapsul
dna
gave
undetect
respons
soon
herrmann
group
use
method
oral
immun
mice
relev
antigen
capsid
protein
rotaviru
chen
et
al
herrmann
et
al
herrmann
et
al
use
rotaviru
dna
vaccineencapsul
plga
microparticl
chen
et
al
report
one
dose
vaccin
given
balbc
mice
elicit
rotavirusspecif
serum
antibodi
intestin
iga
moreov
challeng
homolog
rotavirus
viru
shed
reduc
significantli
compar
control
mice
immun
plga
microparticl
encapsul
plasmid
similar
result
observ
gene
replac
andor
herrmann
et
al
studi
repres
first
demonstr
protect
infecti
agent
oral
administr
dna
vaccin
mani
studi
demonstr
preclin
efficaci
dna
vaccin
diseas
model
infecti
diseas
cancer
allergi
autoimmun
diseas
interest
reader
may
refer
supplement
tabl
tabul
gurunathan
et
al
comprehens
list
allergi
autoimmun
diseas
bacteri
infect
tumor
model
dna
vaccin
attempt
mani
ad
sinc
ctl
antibodi
differ
type
tcell
helper
respons
gener
depend
diseas
antigen
anim
rout
administr
immun
plasmid
dna
induc
antibodi
respons
varieti
protein
anim
speci
particularli
mous
moreov
humor
respons
gener
dna
vaccin
shown
protect
sever
anim
model
vivo
howev
detail
later
antibodi
respons
human
dna
vaccin
encourag
antibodi
respons
dna
vaccin
weak
begin
peak
reach
plateau
month
singl
dna
immun
mice
deck
et
al
furthermor
within
certain
dose
rang
antibodi
product
gener
increas
doserespons
manner
either
singl
inject
multipl
inject
dna
variou
rout
immun
deck
et
al
result
antibodi
respons
long
live
eg
signific
serum
level
present
year
vaccin
deck
et
al
raz
et
al
unfortun
antibodi
respons
dna
protein
live
viru
vaccin
compar
respons
dna
vaccin
gener
weaker
proteinbas
vaccin
liver
viru
vaccin
exampl
studi
compar
antibodi
respons
dna
encod
hemagglutinin
ha
antigen
live
influenza
infect
antibodi
titer
mice
vaccin
live
influenza
significantli
higher
dnavaccin
mice
deck
et
al
compar
antibodi
respons
elicit
vaccin
dna
encod
malari
surfac
protein
protein
antibodi
titer
avid
significantli
lower
mice
vaccin
dna
vaccin
protein
kang
et
al
contrast
one
studi
directli
compar
kinet
antibodi
respons
vaccin
dnaencod
ovalbumin
ova
ova
protein
appear
differ
total
ovaspecif
antibodi
product
week
postvaccin
dna
administ
intraderm
boyl
et
al
studi
antibodi
induc
dna
higher
avid
induc
protein
worthwhil
point
mani
paramet
affect
result
comparison
first
difficult
choos
dose
dna
protein
compar
therefor
one
compar
highest
antibodi
respons
dna
vaccin
highest
antibodi
respons
vaccin
second
well
known
protein
inject
alon
usual
weak
immun
respons
induc
thu
adjuv
alum
often
use
case
dna
vaccin
intramuscular
inject
nake
dna
alon
lead
antibodi
respons
third
adjuv
deliveri
system
make
differ
term
result
respons
exampl
previou
studi
found
antibodi
respons
dna
vaccin
weaker
proteinbas
vaccin
adjuv
alum
dna
vaccin
administ
nake
unformul
plasmid
howev
plasmid
formul
nanoparticl
carrier
result
antibodi
respons
stronger
proteinbas
vaccin
cui
mumper
final
rout
administr
signific
effect
mention
earlier
plasmid
dna
appli
rabbit
buccal
mucosa
via
mucoadhens
film
develop
strong
antibodi
respons
observ
howev
protein
antigen
encod
plasmid
appli
rabbit
rout
devic
detect
antibodi
respons
induc
cui
mumper
therefor
caution
appli
carri
comparison
howev
gener
especi
clinic
trial
antibodi
respons
dna
vaccin
encourag
dna
vaccin
induc
product
mani
subtyp
antibodi
includ
igg
igm
iga
moreov
case
antibodi
gener
dna
vaccin
skew
toward
due
fact
cpg
motif
plasmid
dna
stimul
product
cytokin
howev
except
exist
dna
vaccin
gene
gun
skin
preferenti
bia
toward
product
feltquat
et
al
one
reason
explain
dna
vaccin
administr
via
gene
gun
skin
dna
dose
much
lower
case
intramuscular
inject
therefor
may
suffici
amount
cpg
motif
administ
yet
confirm
final
regard
memori
humor
respons
shown
mice
vaccin
dna
encod
influenza
viral
ha
antigen
level
antiha
antibodi
compar
greater
convalesc
sera
previous
infect
mice
persist
year
martin
et
al
torr
et
al
howev
studi
plasmid
dna
encod
nucleoprotein
lcmv
viru
administ
intramuscularli
fail
give
appreci
antibodi
respons
viral
challeng
deck
et
al
thu
depend
type
antigen
use
dna
vaccin
may
effect
induc
longterm
antibodi
respons
anim
speci
mention
earlier
one
advantag
dna
vaccin
induc
cellular
immun
respons
includ
ctl
respons
safeti
concern
pose
replic
vaccin
live
viru
tcell
respons
tcell
respons
ie
ctl
dna
vaccin
discuss
function
cell
may
divid
research
propos
cell
popul
function
cell
howev
other
believ
cell
may
physic
mixtur
two
cell
produc
ifnexclus
wherea
cell
produc
exclus
also
presenc
cytokin
facilit
differenti
cell
toward
phenotyp
prevent
develop
wherea
presenc
cytokin
allow
differenti
prevent
differenti
cell
cell
mediat
least
three
major
function
activ
cell
promot
bcell
surviv
antibodi
product
banchereau
et
al
cell
product
andor
costimul
provid
helper
function
cell
bennett
et
al
ridg
et
al
schoenberg
et
al
cell
secret
varieti
cytokin
regul
result
immun
respons
mention
previous
cpg
motif
bacteri
dna
induc
product
varieti
proinflammatori
cytokin
includ
tnf
inf
understand
dna
vaccin
gener
skew
respons
toward
scientist
taken
advantag
properti
dna
vaccin
develop
vaccin
tumor
need
strong
especi
ctl
respons
kill
also
dna
vaccin
use
treat
allergi
associ
highlevel
product
ige
antibodi
cytokin
exampl
roy
et
al
develop
chitosanencapsul
dna
vaccin
peanut
allergi
mice
receiv
chitosanencapsul
dna
contain
domin
peanut
allergen
gene
produc
secretori
iga
serum
compar
nonimmun
mice
mice
treat
nake
dna
mice
immun
chitosanencapsul
dna
show
substanti
reduct
allergeninduc
anaphylaxi
associ
reduc
level
ige
plasma
histamin
vascular
leakag
dna
vaccin
abl
gener
antigen
endogen
make
access
cell
via
mhc
class
pathway
numer
public
demonstr
induct
ctl
respons
dna
vaccin
although
ctl
respons
also
induc
live
vaccin
difficult
induc
proteinbas
vaccin
cours
proper
deliveri
system
particl
proteinbas
vaccin
occasion
induc
ctl
respons
falo
et
al
depend
diseas
model
use
magnitud
ctl
respons
dna
vaccin
case
compar
live
viral
vaccin
also
dna
vaccin
induc
ctl
respons
domin
subdomin
epitop
may
use
develop
dna
vaccin
tumor
immunotherapi
develop
process
tumor
cell
often
becom
toler
ctl
respons
domin
epitop
tumorspecif
tumorassoci
antigen
therefor
success
induct
ctl
respons
subdomin
epitop
antigen
help
tumor
kill
memori
cellular
immun
respons
shown
frequenc
antigenspecif
cell
measur
prolifer
remain
elev
week
postvaccin
also
raz
et
al
report
singl
intraderm
needl
inject
g
nake
plasmid
dna
induc
antiinfluenza
nucleoproteinspecif
antibodi
ctl
persist
least
week
vaccin
raz
et
al
separ
studi
davi
et
al
report
ctl
respons
dna
vaccin
hepat
b
viru
envelop
protein
could
detect
month
postvaccin
also
chen
et
al
show
ctl
activ
specif
domin
subdomin
epitop
sendai
viru
nucleoprotein
gene
could
recal
readili
year
dna
vaccin
frequenc
ctl
precursor
specif
epitop
rel
high
chattergoon
et
al
report
coadministr
encod
plasmid
plasmid
encod
hiv
influenza
hemagglutinin
significantli
enhanc
result
ctl
respons
also
led
persist
ctl
respons
summari
depend
rout
antigen
speci
dna
vaccin
may
induc
comprehens
potent
immun
respons
success
dna
vaccin
varieti
small
anim
model
propel
number
human
clinic
trial
diseas
pathogen
includ
hiv
macgregor
et
al
macgregor
et
al
ugen
et
al
weber
et
al
malaria
epstein
et
al
le
et
al
mcconkey
et
al
moorthi
et
al
wang
et
al
wang
et
al
hepat
b
roy
et
al
tacket
et
al
human
papillomaviru
hpv
anal
dysplasia
klenck
et
al
mani
cancer
mincheff
et
al
rosenberg
et
al
tagawa
et
al
timmerman
et
al
select
diseas
model
human
clinic
trial
clearli
show
research
take
advantag
abil
dna
vaccin
induc
cellular
immun
respons
mention
earlier
vaccin
effect
dna
vaccin
tagawa
et
al
diseas
pathogen
believ
strong
specif
ctl
respons
well
antibodi
respons
requir
gener
dna
vaccin
found
safe
human
well
toler
weak
minor
local
side
effect
observ
small
portion
particip
depend
differ
rout
administr
humor
cellular
immun
respons
gener
howev
immun
respons
especi
antibodi
respons
encourag
trial
follow
find
report
dna
vaccin
clinic
trial
tabl
provid
brief
summari
clinic
trial
data
first
human
trial
dna
vaccin
treatment
hiv
infect
report
macgregor
et
al
studi
dnabas
vaccin
encod
env
rev
gene
test
safeti
host
immun
respons
asymptomat
hivinfect
patient
success
group
receiv
three
dose
vaccin
intramuscularli
g
interv
doseescal
trial
vaccin
induc
local
system
reaction
laboratori
abnorm
detect
specif
patient
develop
antidna
antibodi
show
muscl
enzym
elev
consist
chang
occur
lymphocyt
count
plasma
hiv
concentr
antibodi
increas
individu
patient
group
increas
note
ctl
activ
target
lymphocyt
prolif
activ
treatment
elisa
show
bind
antisera
subject
increas
significantli
vaccin
bind
preand
postvaccin
antisera
loop
peptid
deriv
measur
enhanc
bind
dilut
postvaccin
observ
data
demonstr
dna
vaccin
boost
antibodi
respons
human
case
cellular
immun
respons
chang
note
ctl
activ
target
enhanc
specif
lymphocyt
prolif
activ
envelop
observ
multipl
patient
major
patient
exhibit
increas
immun
paramet
within
dose
group
group
highest
dose
least
one
multipl
assay
six
subject
receiv
dose
dna
vaccineinduc
antigenspecif
lymphocyt
prolif
respons
antigenspecif
product
ifnand
chemokin
furthermor
four
five
subject
dose
group
respond
rev
env
compon
vaccin
respons
persist
within
inocul
individu
score
differ
individu
differ
time
trial
macgregor
et
al
macgregor
et
al
macgregor
et
al
ugen
et
al
taken
togeth
studi
show
safeti
profil
dna
vaccin
excel
humor
cellular
immun
respons
includ
ctl
induc
human
also
vaccin
stimul
multipl
immun
respons
vaccinena
subject
multipl
antigen
encod
plasmid
dna
addit
work
weiner
colleagu
weber
et
al
report
phase
studi
dna
vaccin
asymptomat
subject
lymphocyt
count
inject
intramuscularli
four
time
g
env
rev
code
dna
vaccin
week
dna
vaccin
safe
induc
antidna
autoimmun
antibodi
vaccin
longterm
effect
lymphocyt
count
plasma
rna
concentr
diseas
progress
howev
antibodi
titer
chang
significantli
time
period
week
increas
respons
vaccin
compar
baselin
valu
word
dna
vaccin
caus
signific
antibodi
respons
weber
et
al
calarota
et
al
howev
report
vaccin
gene
combin
rais
broad
hivspecif
ctl
respons
calarota
et
al
trial
efficaci
combin
dna
plasmid
encod
nef
rev
tat
regulatori
gene
induc
cellular
immun
respons
analyz
asymptomat
patient
patient
initi
select
low
detect
immun
respons
nef
rev
tat
antigen
develop
mhc
class
irestrict
cytolyt
activ
well
enhanc
bystand
effect
remark
chang
observ
immun
gene
combin
increas
ctl
precursor
target
cell
infect
whole
genom
calarota
et
al
vitro
assess
express
singl
combin
gene
product
show
consist
induct
ctl
respons
vivo
malaria
increasingli
uncontrol
public
health
problem
million
peopl
die
annual
plasmodium
falciparum
infect
prevent
vaccin
like
among
effect
mean
control
wang
colleagu
report
induct
antigenspecif
ctl
respons
human
malaria
dna
vaccin
studi
healthi
adult
volunt
enrol
phase
safeti
toler
clinic
studi
dna
vaccin
encod
malaria
antigen
volunt
receiv
three
intramuscular
inject
one
four
differ
dosag
g
p
falciparum
circumsporozoit
protein
pfcsp
encod
plasmid
dna
monthli
interv
follow
month
local
reactogen
system
symptom
mild
sever
seriou
advers
event
clinic
signific
biochem
hematolog
chang
detect
antidna
antibodi
volunt
develop
antigenspecif
genet
restrict
tcelldepend
ctl
respons
direct
peptid
test
restrict
six
human
lymphocyt
antigen
hla
class
allel
first
demonstr
healthi
human
induct
ctl
dna
vaccin
includ
ctl
restrict
multipl
hla
allel
individu
howev
disappointingli
despit
induct
excel
ctl
respons
dna
vaccin
fail
induc
detect
antigenspecif
antibodi
volunt
le
et
al
wang
et
al
recent
group
report
patient
receiv
pfcsp
dna
vaccin
follow
recombin
protein
vaccin
antibodi
tcell
respons
suggest
heterolog
primeboost
approach
might
viabl
epstein
et
al
wang
et
al
hill
colleagu
univers
oxford
approach
altern
dose
dna
vaccin
recombin
modifi
vaccinia
viru
ankara
mva
mcconkey
et
al
moorthi
et
al
show
heterolog
primeboost
vaccin
regim
dna
either
intramuscularli
epiderm
follow
intraderm
recombin
mva
induc
high
frequenc
ifn
secret
antigenspecif
tcell
respons
human
preerythrocyt
malaria
antigen
thrombospondinrel
adhes
protein
trap
respons
higher
tcell
respons
induc
dna
vaccin
recombin
mva
vaccin
alon
produc
partial
protect
manifest
delay
parasitemia
sporozoit
challeng
differ
strain
p
falciparum
dna
metrap
mva
metrap
safe
immunogen
effector
memori
tcell
induct
mva
metrap
without
prior
dna
metrap
immun
immunogen
crossreact
malariaexpos
individu
malariana
individu
cell
induc
vaccin
mcconkey
et
al
moorthi
et
al
tacket
et
al
report
hbv
dna
vaccin
human
trial
studi
design
determin
safeti
immunogen
dna
vaccin
consist
plasmidencod
hepat
b
surfac
antigen
hbsag
deliv
powderject
gene
deliveri
system
human
skin
seven
healthi
adult
volunt
receiv
two
immun
day
vaccin
well
toler
howev
one
six
seroneg
volunt
develop
high
titer
persist
antihbsag
ab
singl
immun
tacket
et
al
reason
lack
immun
respons
might
due
extrem
low
dna
dose
g
use
similar
trial
carri
powderject
vaccin
inc
produc
quit
differ
encourag
result
roy
et
al
report
induct
antigenspecif
cell
helper
cell
protect
level
antibodi
human
particlemedi
administr
hepat
b
viru
dna
vaccin
skin
needlefre
powderject
system
use
deliv
gold
particl
coat
dna
directli
cell
skin
healthi
hepatitisna
human
volunt
three
group
four
volunt
receiv
three
administr
dna
encod
surfac
antigen
hbv
one
three
dose
level
g
vaccin
safe
well
toler
caus
transient
mild
moder
respons
site
administr
volunt
develop
protect
antibodi
respons
least
miuml
volunt
posit
hla
class
allel
vaccin
also
induc
antigenspecif
cell
bound
hbsag
tetram
secret
ifn
lyse
target
cell
present
hbsag
ctl
epitop
roy
et
al
result
demonstr
dna
vaccin
may
induc
protect
antibodi
titer
human
depend
dna
vaccin
administr
hpv
anal
dysplasia
klenck
colleagu
ucsf
test
plga
microsphereencapsul
dna
vaccin
develop
zyco
inc
lexington
treat
hpv
anal
dysplasia
highgrad
dysplasia
induc
highrisk
type
human
papillomaviru
hpv
preced
invas
cancer
anal
squamou
epithelium
cervix
trial
subject
treat
four
im
inject
g
interv
plasmid
dna
encod
multipl
epitop
deriv
protein
one
two
hpv
oncoprotein
consist
express
neoplast
cell
twelv
elig
subject
anal
infect
haplotyp
enrol
studi
well
toler
subject
dose
level
test
three
subject
experienc
partial
histolog
respons
includ
subject
receiv
dose
subject
dose
level
use
direct
elispot
subject
demonstr
increas
immun
respons
peptid
epitop
encod
within
continu
show
elev
immun
respons
month
initi
therapi
requir
ctl
respons
kill
tumor
cell
abil
induc
cellular
immun
respons
dna
vaccin
make
attract
develop
cancer
vaccin
advanc
biochem
genet
techniqu
last
decad
facilit
discoveri
great
number
tumorspecif
antigen
tsa
tumorassoci
antigen
taa
anim
studi
tumor
dna
vaccin
proven
effect
although
tumor
graft
artifici
almost
case
success
preclin
data
propel
tumor
dna
vaccin
human
trial
mincheff
cowork
publish
result
trial
nake
dna
adenovir
immun
immunotherapi
prostat
cancer
prostatespecif
membran
antigen
psma
use
tumor
antigen
immun
includ
extracellular
human
psma
dna
well
human
dna
separ
express
vector
psma
plasmid
combin
plasmid
addit
psma
gene
insert
replicationdefici
adenovir
express
vector
twentysix
patient
prostat
cancer
enter
phase
iii
toxicitydos
escal
studi
immun
perform
intraderm
weekli
interv
dose
dna
g
recombin
viru
pfu
per
applic
use
found
immedi
longterm
side
effect
follow
immun
patient
receiv
initi
inocul
viral
vector
follow
psma
plasmid
boost
show
sign
immun
evidenc
develop
delayedtyp
hypersensit
reaction
psma
plasmid
inject
contrast
patient
receiv
psma
plasmid
plasmid
show
sign
success
immun
patient
receiv
psma
plasmid
solubl
granulocytemacrophag
colonystimul
factor
gmcsf
immun
howev
patient
receiv
plasmid
solubl
gmcsf
becam
immun
patient
immun
first
round
later
success
immun
boost
viral
vector
heterogen
medic
statu
presenc
concomit
hormon
therapi
mani
patient
permit
unequivoc
interpret
data
respect
effect
therapi
howev
sever
respond
evidenc
chang
local
diseas
distant
metastas
psa
level
identifi
conri
et
al
report
safeti
immunogen
result
doseescal
clinic
trial
dual
express
plasmid
encod
carcinoembryon
antigen
cea
hbsag
patient
metastat
colorect
carcinoma
conri
et
al
cea
select
prototyp
tumorassoci
selfantigen
hbsag
cdna
includ
posit
control
immun
respons
dna
vaccin
without
reli
break
toler
selfantigen
group
patient
receiv
escal
singl
im
dose
dna
vaccin
mg
subsequ
group
patient
receiv
three
repetit
dose
interv
final
group
patient
receiv
three
repetit
dose
interv
toxic
limit
transient
grade
inject
site
tender
fatigu
creatin
kinas
elev
affect
minor
patient
nondoserel
manner
repetit
dose
dna
vaccin
induc
hbsag
antibodi
patient
protect
antibodi
level
achiev
patient
although
patient
develop
lymphoprolif
respons
cea
vaccin
ceaspecif
antibodi
respons
observ
subject
echo
result
human
clinic
trial
mention
earlier
also
studi
show
antibodi
respons
depend
antigen
use
hbsag
known
antigen
probabl
antihbsag
ab
detect
patient
anticea
ab
detect
individu
object
clinic
respons
dna
vaccin
observ
among
popul
patient
wide
metastat
colorect
carcinoma
levi
colleagu
report
result
dna
vaccin
encod
chimer
idiotyp
patient
bcell
lymphoma
timmerman
et
al
bcell
lymphoma
express
tumorspecif
immunoglobulin
variabl
region
idiotyp
id
serv
target
activ
immunotherapi
safeti
immunogen
nake
dna
id
vaccin
patient
follicular
bcell
lymphoma
investig
dna
encod
chimer
immunoglobulin
molecul
contain
variabl
heavi
light
chain
immunoglobulin
sequenc
deriv
patient
tumor
link
mous
immunoglobulin
msig
heavi
light
chain
constant
region
chain
respect
patient
remiss
chemotherapi
receiv
three
monthli
im
inject
dna
three
doseescal
cohort
patient
g
vaccin
patient
mount
either
humor
n
tcellprolif
n
respons
msig
compon
vaccin
one
patient
tcell
respons
specif
autolog
id
also
measur
second
seri
vaccin
administ
use
needlefre
inject
devic
biojector
deliv
g
im
intraderm
id
patient
humor
n
andor
tcell
n
respons
msig
six
patient
exhibit
humor
andor
tcell
antiid
respons
howev
crossreact
id
protein
patient
tumor
subsequ
third
seri
vaccin
carri
use
g
human
granulocytemacrophag
colonystimul
factor
dna
mix
g
id
dna
proport
patient
respond
msig
remain
essenti
unchang
although
humor
tcell
respons
boost
case
throughout
studi
signific
side
effect
toxic
observ
result
rosenberg
et
al
nci
dna
vaccin
encod
melanomamelanocyt
antigen
patient
metastat
melanoma
report
disappoint
studi
patient
metastat
melanoma
random
receiv
plasmid
dna
either
intraderm
n
intramuscularli
n
one
patient
exhibit
partial
respons
sever
subcentimet
cutan
nodul
patient
progress
diseas
patient
cell
avail
immun
patient
exhibit
evid
develop
cell
respons
use
vitro
boost
assay
unabl
demonstr
signific
immunolog
clinic
respons
plasmid
dna
encod
self
nonmut
tumor
antigen
studi
carri
tagawa
et
al
melanoma
dna
vaccin
encod
tyrosinas
epitop
encourag
tagawa
et
al
group
eight
stage
iv
melanoma
patient
receiv
g
dna
intranod
pump
h
everi
day
four
cycl
blood
collect
immunolog
assay
measur
plasmid
serum
prior
treatment
week
later
scan
xray
perform
baselin
week
found
treatment
well
toler
five
patient
demonstr
grade
toxic
vaccin
infus
plasmid
groin
lymph
node
result
one
episod
cathet
leakag
cannul
detect
plasmid
serum
rare
transient
two
patient
immun
respons
peptidetetram
assay
tyrosinas
amino
acid
detect
patient
although
clinic
respons
seen
surviv
heavili
pretreat
patient
trial
unexpectedli
long
patient
aliv
median
followup
month
failur
dna
vaccin
human
trial
tumor
agre
well
report
tumor
immunotherapi
human
trial
vaccin
possibl
reason
includ
crippl
immun
system
cancer
patient
especi
chemotherapi
andor
radiotherapi
addit
tumor
develop
great
number
escap
mechan
loss
mhc
molecul
make
tumor
cell
unrespons
ctl
kill
summari
mani
human
clinic
trial
report
past
sever
year
dna
vaccin
quit
diseas
model
although
shown
dna
vaccin
safe
caus
minor
side
effect
result
immunolog
respons
encourag
low
antibodi
respons
detect
case
often
clinic
respons
somewhat
weak
cellular
respons
trial
therefor
research
transfer
success
dna
vaccin
small
anim
larg
anim
human
urgent
need
although
dna
vaccin
thought
safer
tradit
live
viral
vaccin
phase
clinic
trial
report
seriou
side
effect
dna
vaccin
still
sever
concern
includ
integr
plasmid
dna
host
genom
induct
autoimmun
respons
induct
toler
instead
immun
effect
cpg
motif
overal
longterm
immun
respons
organ
fda
european
union
alreadi
guidelin
regul
dna
vaccin
document
list
manufactur
preclin
human
clinic
issu
relev
develop
dna
vaccin
describ
potenti
safeti
concern
vaccin
develop
address
prior
initi
clinic
trial
sever
issu
mention
earlier
discuss
briefli
similar
gene
therapi
widespread
concern
plasmid
dna
might
integr
host
genom
increas
chanc
malign
transform
genom
instabl
cell
growth
dysregul
howev
mani
year
integr
plasmid
dna
host
genom
report
make
difficult
reach
regulatori
consensu
concern
magnitud
problem
gurunathan
et
al
well
known
technic
easi
remov
free
plasmid
dna
host
genom
dna
wang
et
al
clearli
show
integr
plasmid
dna
mous
genom
especi
intramuscular
dna
electropor
wang
et
al
needleinject
mice
copi
plasmid
dna
detect
g
genom
dna
agre
well
previou
report
indic
earli
copi
dna
vaccin
plasmid
associ
host
genom
dna
month
intramuscular
needl
inject
ledwith
et
al
martin
et
al
calcul
mutat
rate
copi
per
genom
time
lower
spontan
mutat
rate
per
cell
howev
plasmid
dna
copi
genom
dna
detect
polymeras
chain
reaction
pcr
pcr
may
abl
detect
integr
short
fragment
addit
effect
integr
long
stretch
plasmid
dna
contain
strong
regulatori
sequenc
might
signific
small
spontan
point
mutat
integr
rate
howev
sharpli
increas
copiesg
genom
dna
case
electropor
dna
wang
et
al
electropor
increas
plasmid
tissu
level
approxim
use
quantit
gel
purif
assay
integr
electropor
found
markedli
increas
level
plasmid
associ
genom
dna
confirm
integr
identifi
insert
site
wang
et
al
develop
new
assay
refer
repeatanchor
integr
captur
raic
pcr
capabl
detect
rare
integr
event
complex
mixtur
vivo
use
assay
identifi
four
independ
integr
event
sequenc
insert
site
suggest
random
integr
process
short
segment
homolog
vector
breakpoint
insert
site
three
four
case
highlight
dilemma
scientist
face
way
improv
effici
dna
vaccin
electropor
might
time
increas
risk
integr
dna
vaccin
therefor
necessari
continu
monitor
integr
rate
dna
administr
approach
prior
entranc
human
clinic
trial
note
earlier
cpg
motif
plasmid
dna
bias
immun
respons
toward
could
deleteri
humor
respons
requir
therefor
increas
suscept
host
infect
need
respons
addit
respons
long
term
might
lead
develop
organspecif
autoimmun
diseas
segal
et
al
report
murin
model
cpg
motif
enhanc
product
promot
develop
experiment
allerg
encephalomyel
organspecif
autoimmun
diseas
klinman
et
al
report
repeatedli
administ
ip
cpg
odn
two
four
time
month
anim
remain
healthi
develop
neither
macroscop
microscop
evid
tissu
damag
inflamm
contrast
heikenwald
et
al
report
repeat
cpg
odn
administr
led
lymphoid
follicl
destruct
immunosuppress
conflict
data
clearli
show
thorough
studi
need
carri
investig
longterm
effect
cpg
motif
mor
colleagu
report
dna
vaccin
encod
circumsporozoit
protein
malaria
induc
toler
rather
immun
administ
mice
although
induc
strong
protect
immun
respons
live
sporozoit
challeng
adult
balbc
mice
mor
et
al
neonat
toler
anim
unabl
mount
antibodi
cytokin
cytotox
respons
rechalleng
dna
vaccin
vitro
vivo
toler
specif
immunogen
epitop
express
vaccineencod
endogen
produc
antigen
confirm
neonat
endogen
present
antigen
dna
vaccin
might
view
neonat
self
howev
studi
point
whether
toler
immun
develop
depend
mani
paramet
dose
recipi
age
natur
antigen
ichino
et
al
exampl
influenza
rabi
hbv
toler
observ
even
neonat
final
decreas
respons
also
observ
age
mice
year
old
suggest
dna
vaccin
might
effect
elderli
peopl
bender
et
al
probabl
due
gener
weaker
immun
system
elderli
peopl
sinc
first
discoveri
great
advanc
made
dna
vaccin
field
dna
vaccin
proven
success
mani
diseas
small
anim
model
howev
recent
clinic
trial
shown
far
effect
human
research
transfer
success
dna
vaccin
small
anim
human
thu
need
